# SBC earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/SBC) · [Earnings tab](https://www.lopjlb.com/stock/SBC?tab=earnings) Updated: 2026-11-14T06:11:45 Quarters analyzed: 2 ## Cross-quarter narrative Between Q2 and Q3 2026, SBC accelerated top-line growth from 13% to 35% YoY, driven by same-clinic revenue (+7%), visit growth (+9%), and higher spend per visit (+4%). Adjusted EBITDA margin expanded 6 percentage points to 47%, reflecting operating leverage at the MSO level. Clinic count grew modestly to 293 (+6 QoQ). The company deepened its AI strategy, detailing a local LLM foundation and six AI features, while advancing longevity initiatives with a blood biomarker testing program and an online coaching platform, though meaningful revenue from longevity is not expected until 2028. US expansion entered execution phase via an OrangeTwist minority stake and planned SBC-branded clinics (6-12 month timeline). Capital allocation shifted explicitly toward M&A and de novo openings, with no share buyback despite a low valuation (~4x adj EBITDA, ~20% FCF yield). New governance concerns emerged: founder holds ~80% shares, independent directors not yet appointed. Analysts questioned sustainability of 35% revenue growth and 66% operating income growth; management acknowledged short-term fluctuation but expressed mid-to-long-term confidence. Key delays include unspecified AI monetization timeline, pending independent director appointments, and US clinic launch timeline.','theme_arcs ## Latest CallCard · Q3 SBC Q3 2026: Revenue +35% YoY to $59M, op income +66%, adj EBITDA margin 47% (+9pp). Same-clinic revenue +7% (9M), visits +9%, spend/visit +4%. 293 clinics (+36). Longevity roadmap through 2028, local LLM AI, US expansion via OrangeTwist, M&A planned. No buyback, prioritizing M&A/de novo. Governance **Guidance:** vague — Management expresses confidence in mid-to-long-term growth and margin expansion but provides no quantitative guidance. Qualitative outlook: 'confident it will continue over the mid to long-term', 'big room for the margin to expand in the near future', 'meaningful revenue contribution from around 2028' for longevity. **Tone:** mgmt 0.8 · Q&A pressure 0.6 · divergence 0.2 Prepared remarks emphasize 'growth clearly re-accelerated', 'operating leverage built into our MSO model', 'confident in SBC's trajectory', and 'high growth, high and rising margins, net cash balance sheet'. ### Demand visibility Strong underlying clinic demand: same-clinic revenue +7% (9M), visits +9%, spend/visit +4% driven by strategic pricing, new equipment, multi-brand strategy. Growth driven by strategic pricing over past two years establishing competitive position, introduction of state-of-the-art equipment (NEO Skin Clinic laser network), and multi-brand rollout (SBC Skin Clinic, MEN'S FLASH CLINIC, JUN CLINIC) capturing diversified needs. Competitive environment favorable after restructuring. Non-aesthetic expansion (dentistry, orthopedics, ophthalmology) and M&A planned for 2027. ### Margins / costs Adj EBITDA margin 47% (+9pp YoY) reflecting MSO operating leverage. Two drivers expected to expand margins further: AI-driven service fee expansion and network scale leverage. Driver 1: Service fee expansion from higher clinic productivity via AI (local LLM with NeuroBrain Dynamics/AtomicSoftware, voice-to-EMR automation, AI shift scheduling) decoupled from cloud API costs. Driver 2: Network expansion as MSO increases platform leverage and organizational efficiency. Management sees 'big room for the margin to expand in the near future'. ### Capital allocation Prioritizing M&A and de novo clinic openings for longevity/AI growth; improving liquidity; no share buyback despite low valuation. Cash >$200M. Priority 1: Invest in M&A and de novo clinics to expand network for longevity and AI initiatives. Priority 2: Improve liquidity (daily trading value ~$1M, 4.1x July; shareholders 7,300, 1.6x July). Not considering buyback: 'liquidity itself is improving significantly... we expect our free float and liquidity continue expanding steadily.' Funded by operating cash flow, no dilution needed. ### Milestones - **Blood biomarker testing program (DNA methylation test)** [new]: In-house development starting November 2026, leveraging Waqoo Group regenerative medicine research. Pillars: organ-by-organ biological age mapping, non-invasive measurement methods, Japan-specific data. - **Longevity center + online coaching/tracking platform** [new]: Targeted for 2027 establishment as part of longevity roadmap through 2028. - **AI-generated doctor-verified treatment protocols** [new]: Planned for 2027-2028, combining clinical data with AI for personalized care. - **US expansion via OrangeTwist and SBC-branded clinics** [on_track]: OrangeTwist (minority stake) expanding med spa network: 8-10 new clinics in next 3-4 months. SBC-branded clinics expected in 6-12 months. Also exploring other partnerships and Southeast Asia. - **Local LLM foundation and six AI features** [on_track]: Capital/business alliance with AtomicSoftware (medicalforce). Six features: voice-driven charting, AI shift scheduling, clinical monitoring, promotion planner, treatment recommendation engine, personalized recommendations. Decoupled from cloud API costs. - **Clinic network expansion to 293 locations (+36 YoY)** [on_track]: Continuing similar pace in 2027 for aesthetic clinics, plus non-aesthetic (dentistry, orthopedics, ophthalmology) and M&A for both aesthetic and general medicine networks. - **Multi-brand strategy rollout** [delivered]: SBC Skin Clinic (dermatology rebrand), MEN'S FLASH CLINIC, JUN CLINIC performing well, capturing diversified customer needs. - **Governance: independent director selection** [on_track]: Process advancing concretely; aim to report new board composition at earliest timing. Seeking diverse expertise representing minority shareholders. ### Fears / risks - **Growth sustainability**: Analysts question whether 35% revenue growth and 66% op income growth are sustainable; management acknowledges short-term fluctuation but confident mid-to-long-term. - **US execution risk**: OrangeTwist minority stake limits control; SBC-branded clinics unproven in US market; timeline 6-12 months for first locations. - **Longevity market immaturity**: Longevity trend in Japan 'still emerging, not as developed as US'; meaningful revenue only from ~2028. - **Governance concerns**: Founder holds ~80% shares; independent directors not yet appointed; investors demand board representation for minority shareholders. - **Valuation discount persistence**: Stock trades at ~4x Q3 adj EBITDA and ~20% FCF yield; management not pursuing buyback despite cheap valuation. - **Competitive intensity in Japan**: Several clinics exiting market due to pricing pressure; could signal market saturation or deflationary pressure. - **AI development risk**: Local LLM and six AI features in development; cost savings and revenue uplift not yet quantified; execution risk on proprietary features. - **M&A integration risk**: Planned acquisitions for both aesthetic and general medicine networks; integration of diverse clinic formats and cultures. ### Key quotes > “If I had to sum up this quarter in a single sentence, it is the quarter in which SBC's growth clearly re-accelerated. Revenue rose 35% year-on-year. Income from operations grew 66%, and our adjusted EBITDA margin reached 47%.” > “Profit grew twice as fast as revenue, and that is not a good quarter. That is a business model working. Our clinics grow, our headcount does not, and the difference is your margin. Margin improvement will continue.” ## Quarter one-liners - **2026 Q3:** SBC Q3 2026: Revenue +35% YoY to $59M, op income +66%, adj EBITDA margin 47% (+9pp). Same-clinic revenue +7% (9M), visits +9%, spend/visit +4%. 293 clinics (+36). Longevity roadmap through 2028, local LLM AI, US expansion via OrangeTwist, M&A planned. No buyback, prioritizing M&A/de novo. Governance - **2026 Q2:** SBC Q2 2026: revenue $49M (+13%), adj EBITDA $20M (+32%, 41% margin); 287 clinics (+34 YoY), visits 6.92M (+10%); multi-brand expansion, non-aesthetic push, AI-driven efficiency, longevity center 2027, targeting 1,000 clinics by 2035.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Management highlighted ## Guidance path 2026 Q2:vague → 2026 Q3:vague --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/SBC`